
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145835110.1021/acsomega.8b02755ArticleSynthesis of Pyrimidine- and Quinazoline-Fused Benzimidazole-4,7-diones
Using Combinatorial Cyclocondensation and Oxidation Kim Dong Young Quang Dao Pham Duy Cho Chan Sik *Department of Applied Chemistry, Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic
of Korea* E-mail: cscho@knu.ac.kr (C.S.C.).17 12 2018 31 12 2018 3 12 17456 17465 11 10 2018 20 11 2018 Copyright © 2018 American Chemical Society2018American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

β-Bromo-α,β-unsaturated
aldehydes and 2-bromobenzaldehydes
react with 4,7-dimethoxy-1H-benzo[d]imidazole-2-amine by microwave irradiation in dimethylformamide
in the presence of a base to give the corresponding dimethoxy-substituted
benzo[4,5]imidazo[1,2-a]pyrimidines and benzo[4,5]imidazo[1,2-a]quinazolines, respectively, in moderate to good yields.
Oxidation of such N-fused hybrid scaffolds by aqueous ceric ammonium
nitrate affords pyrimidine- and quinazoline-fused benzimidazole-4,7-diones
in high yields.

document-id-old-9ao8b02755document-id-new-14ao-2018-02755gccc-price
==== Body
Introduction
Besides homonuclear
N-heterocyclic compounds, many synthetic methods
for their N-fused hybrid scaffolds have been attempted and developed
because of characteristic biological activities that are not shown
in each homonuclear scaffolds. It is known that homonuclear pyrimidine-
and benzimidazolequinone (1H-benzo[d]imidazole-4,7-dione)-containing compounds show diverse biological
activities, such as anticancer, antimalarial, antitumor, antiproliferative,
and cytotoxic properties.1,2 There are two N-fused
modes of such homonuclear N-heterocycles, benzo[4,5]imidazo[1,2-a]pyrimidine-6,9-diones (Scheme 1, A) and benzo[4,5]imidazo[1,2-c]pyrimidine-6,9-diones (Scheme 1, B). In contrast to many synthetic
methods for other N-fused hybrid scaffolds, limited examples for the
synthesis of such N-fused hybrid scaffolds A and B are known. It is reported that N-fused hybrid scaffold A can be synthesized by the reaction of 2-aminopyrimidine
with p-chloranil (2,3,5,6-tetrachloro-1,4-benzoquinone)
followed by subsequent treatment with diethylamine and HCl (Scheme 2).3 We reported on the synthesis of N-fused hybrid scaffold B by step-by-step copper-catalyzed coupling and cyclization
of 2-(2-bromovinyl)-4,7-dimethoxybenzimidazoles with primary amides
to form pyrimidine-fused 4,7-dimethoxybenzimidazoles, and oxidation
of such intermediates by aqueous ceric ammonium nitrate (CAN) (Scheme 2).4 As part of our continuing studies directed toward transition
metal–catalyzed and transition metal–free cyclization
reactions for heterocycles,5 we have shown
several new synthetic protocols for N-fused hybrid scaffolds.6 Among them, β-bromo-α,β-unsaturated
aldehydes were found to be cyclocondensed with 2-aminobenzimidazole
in the presence of a base under microwave irradiation to give pyrimidine-fused
benzimidazoles, benzo[4,5]imidazo[1,2-a]pyrimidines.7,8 Under these circumstances, the present work started during the course
of a combinatorial extension of such protocols to develop a new synthetic
approach for N-fused hybrid scaffolds. Herein we provide another example
for the synthetic method of N-fused hybrid scaffold A by sequential cyclocondensation between β-bromo-α,β-unsaturated
aldehydes and 2-aminobenzimidazole analogue, 4,7-dimethoxy-1H-benzo[d]imidazole-2-amine and oxidation
(Scheme 2).

Scheme 1 Two N-Fused
Modes of Benzimidazolequinone and Pyrimidine
Scheme 2 Synthesis of Benzo[4,5]imidazo[1,2-a]pyrimidine-6,9-diones A and Benzo[4,5]imidazo[1,2-c]pyrimidine-6,9-diones B
Results and Discussion
First, we optimized the reaction conditions to produce precursors,
dimethoxy-substituted benzo[4,5]imidazo[1,2-a]pyrimidines
of N-fused hybrid scaffold A effectively. On the basis
of recent reports on transition metal–free cyclocondensation
of β-bromo-α,β-unsaturated aldehydes and 2-halobenzaldehydes
with 2-aminobenzimidazole,7,9Table 1 shows several attempted results for the
cyclocondensation of 2-bromocyclohex-1-enecarbaldehyde (1a) with 4,7-dimethoxy-1H-benzo[d]imidazole-2-amine (2a) under various reaction conditions,
leading to 8,11-dimethoxy-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]quinazoline (3a). The starting 2a was prepared from 3,6-dimethoxybenzene-1,2-diamine2b,10 and cyanogen bromide using similar methods reported.11 Treatment of 1a with equimolar
amount of 2a in dimethylformamide (DMF) at 110 °C
for 1 h in the presence of K2CO3 under microwave
irradiation afforded 3a in 64% isolated yield (Table 1, entry 1). The molar
ratio of 2a to 1a, although not significant,
affected the yield of 3a, and the yield increased with
the increase in the molar ratio up to 1.2 without other identifiable
by-products (Table 1, entries 1–3). Lower yield of 3a was observed
under lower reaction temperature, and the yield increased with the
increase in temperature up to 110 °C (Table 1, entries 2, 4, and 5). Prolonging the reaction
time up to 1 h was needed for the effective formation of 3a with complete conversion of 1a (Table 1, entries 2, 6, and 7). In contrast to the
reaction between β-bromo-α,β-unsaturated aldehydes
and 2-aminobenzimidazoles,7 further addition
of magnesium sulfate resulted in rather decreased yield of 3a (Table 1, entry 8).
The reaction also proceeded in the presence of other inorganic bases
such as K3PO4, NaOtBu, NaOAc, Cs2CO3, and CsF, but the yields
of 3a were generally lower than that obtained in the
presence of K2CO3 (Table 1, entries 9–13).12 Unlike the previous cyclocondensation of β-bromo-α,β-unsaturated
aldehydes and 2-aminobenzimidazoles, no allowable yield of 3a was observed with Et3N (Table 1, entry 14). When 1a was treated
with 2a under usual heating conditions (screw-capped
vial) for 10 h, 3a was obtained in 52% yield (Table 1, entry 15).

Table 1 Optimization of Conditions for the
Reaction of 1a with 2aa
entry	[1a]/[2a]	base	temp. (°C)	time (h)	yield (%)	
1	1/1	K2CO3	110	1	64	
2	1/1.2	K2CO3	110	1	68	
3	1/1.5	K2CO3	110	1	69	
4	1/1.2	K2CO3	85	1	43	
5	1/1.2	K2CO3	135	1	68	
6	1/1.2	K2CO3	110	0.5	51	
7	1/1.2	K2CO3	110	2	70	
8b	1/1.2	K2CO3	110	1	57	
9	1/1.2	K3PO4	110	1	54	
10	1/1.2	NaOtBu	110	1	26	
11	1/1.2	NaOAc	110	1	40	
12	1/1.2	Cs2CO3	110	1	39	
13	1/1.2	CsF	110	1	45	
14	1/1.2	Et3N	110	1	28	
15c	1/1.2	K2CO3	110	10	52	
a 1a (0.3 mmol), base
(0.9 mmol), additive (0.6 mmol), microwave irradiation (100 W initial
power), DMF (3 mL), unless otherwise stated.

b Further addition of MgSO4 (0.6 mmol).

c Under usual heating (screw-capped
vial).

Having optimized
the reaction conditions, various β-bromo-α,β-unsaturated
aldehydes 1 were subjected to the reaction with 2a to investigate the reaction scope, and several representative
results are summarized in Table 2. The cyclocondensation of 2-bromocyclohex-1-enecarbaldehydes
(1b and 1c) with 2a also proceeded
to give the corresponding pyrimidine-fused benzimidazoles (3b and 3c) in similar yields, irrespective of the presence
of the methyl and phenyl substituents on 1b and 1c. With cyclic β-bromo-α,β-unsaturated
aldehydes 1d–f having various ring sizes, the
corresponding N-fused scaffolds 3d–f were also
formed in 72–82% yields. The reaction of benzo-fused β-bromo-α,β-unsaturated
aldehydes 1g took place with 2a to give
8,11-dimethoxy-13,14-dihydrobenzo[f]benzo[4,5]imidazo[1,2-a]quinazoline (3g) in 21% yield along with
its dehydrogenated product 3g′ (35% yield). Performing
the reaction for prolonging reaction time (2 h) under the employed
conditions solely afforded 3g′ in 61% yield. This
result indicates that 3g′ is produced by dehydrogenation
of 3g initially formed by the cyclization of 1g. Such a similar dehydrogenation was observed by our recent reports
on coupling and cyclizaton reactions using similar benzo-fused six-membered
ring substrates.5c,5d,6b,6c Acyclic β-bromo-α,β-unsaturated
aldehydes 1h–o having alkyl and aryl substituents
were also cyclocondensed with 2a to afford pyrimidine-fused
benzimidazoles 3h–o in 55–67% yields and
the product yield was not significantly affected by the identity of
such substituents.

Table 2 Cyclocondensation of 1 with 2a Leading to 3a
a Reaction conditions: 1 (0.3 mmol), 2 (0.36 mmol), K2CO3 (0.9 mmol), DMF (3 mL), 110 °C, 1 h, under microwave
irradiation
(100 W of initial power).

Similar treatment of 2-bromobenzaldehydes (1p and 1q) with 2a under the employed conditions produced
the corresponding quinazoline-fused benzimidazoles (3p and 3q) in 71 and 50% yields, respectively. Benzo-fused
analogue 1r also reacted with 2a to give
such a hybrid scaffold 3r in 63% yield. In contrast to
many synthetic methods for pyrimidine-fused benzimidazoles,8 benzo[4,5]imidazo[1,2-a]pyrimidines,
limited examples are known for the construction of quinazoline-fused
benzimidazoles, benzo[4,5]imidazo[1,2-a]quinazolines.9,13,14 Wang and Singh reported that N-(2-benzimidazoyl)-2-aminobenzamides react with 2-bromobenzaldehydes
in the presence or absence of CuI and l-proline to afford
benzo[4,5]imidazo[1,2-a]quinazolines via Ullmann-type
C–N coupling followed by double C–N bond cleavage.13 Such a similar C–N coupling for eventual
formation of benzo[4,5]imidazo[1,2-a]quinazoline
was also exemplified by copper-catalyzed reaction between 2-bromobenzoic
acid and 2-aminobenzimidazole.14 However,
to the best of our knowledge, no reports are found for the biological
activities of such scaffolds.

As to the reaction pathway, although
it is not certain, this seems
to proceed via an initial formation of Schiff base by condensation
between 1 and 2a. This is followed by intramolecular
nucleophilic aromatic substitution under basic conditions to give 3.9 A reviewer commented on how 1 will behave in reactions with unsymmetrically substituted
2-aminobenzimidazoles having electron-donating and electron-withdrawing
groups. The reaction of 2-bromobenzaldehyde (1p) with
unsymmetrically substituted 2-aminobenzimidazoles (2b and 2c) under the employed conditions afforded the
corresponding cyclocondensation products (3s and 3t) as isomeric mixtures in 30 and 19% yields, respectively
(Scheme 3, see Supporting Information for 1H NMR
spectra).11a

Scheme 3 Reactions with Unsymmetrically
Substituted 2-Aminobenzimidazoles
Oxidation of all pyrimidine- and quinazoline-fused dimethoxybenzimidazoles 3a–r shown in Table 2 except for 3g by treatment of CAN in
aqueous acetonitrile afforded benzo[4,5]imidazo[1,2-a]pyrimidine-6,9-diones and benzo[4,5]imidazo[1,2-a]quinazoline-8,11-diones, respectively, in high yields (Table 3).2b,2j,15 Not fully understood, 3g′ was readily oxidized to the corresponding benzimidazolequinone 4g in similar yield, whereas no expected oxidation product
was observed with 3g. No reports for benzo[4,5]imidazo[1,2-a]quinazoline-8,11-diones are known for synthetic methods
and biological activities.

Table 3 Oxidation of 3–4 with CANa
a Reaction conditions: 3 (0.1 mmol),
CAN (0.3 mmol), acetonitrile/H2O (4 mL),
0 °C, 20 min.

Conclusions
In summary, we have shown that β-bromo-α,β-unsaturated
aldehydes and 2-bromobenzaldehydes trigger cyclocondensation with
4,7-dimethoxy-1H-benzo[d]imidazole-2-amine
under microwave irradiation in the presence of a base to form the
corresponding dimethoxy-substituted benzo[4,5]imidazo[1,2-a]pyrimidines and benzo[4,5]imidazo[1,2-a]quinazolines, respectively. Such scaffolds could be oxidized into
benzo[4,5]imidazo[1,2-a]pyrimidine-6,9-diones and
benzo[4,5]imidazo[1,2-a]quinazoline-8,11-diones by
treatment with aqueous CAN. The present reaction would be served as
a useful method for designing and synthesizing bioreductive quinone-based
drugs. Further studies on the synthesis of unprecedented benzimidazole-based
1,4-quinone-containing N-fused hybrid scaffolds using the present
protocol are expected.

Experimental Section
General Information
1H and 13C NMR spectra were obtained at 500
and 125 MHz, respectively, in
DMSO-d6 or CDCl3. Melting points
were measured on a microscopic melting point apparatus. High-resolution
mass data were recorded using electronic ionization (HRMS-EI, magnetic
sector–electric sector double focusing mass analyzer) at the
Korea Basic Science Center (Daegu). All microwave reactions (CEM,
Discover LabMate) were performed in a 5 mL tube, and maintenance of
the reaction temperature was monitored by an external infrared sensor.
The crude reaction mixtures were purified by thin-layer (a glass plate
coated with Kieselgel 60 GF254, Merck) chromatography.
The starting aldehydes were prepared from the corresponding ketones
according to literature procedures.16 4,7-Dimethoxy-1H-benzo[d]imidazole-2-amine (2a) was prepared from 3,6-dimethoxybenzene-1,2-diamine and cyanogen
bromide using the procedure shown below.17 3,6-Dimethoxybenzene-1,2-diamine was synthesized by a known method
from hydroquinone via a three-step sequence (methylation, nitration,
reduction).2b,10 All other commercially available
chemicals were used without further purification.

Synthesis of
4,7-Dimethoxy-1H-benzo[d]imidazole-2-amine
(2a)
To a solution
of 3,6-dimethoxybenzene-1,2-diamine (1.682 g, 10 mmol) in MeOH/H2O (100 mL, 1:1), cyanogen bromide (3.178 g, 30 mmol) was added.
The reaction mixture was stirred at 50 °C for 3 h. After the
mixture was cooled to room temperature, neutralized with 10% aqueous
NaOH solution (to pH = 10), and extracted with EtOAc (50 mL, 3 times),
the combined organic layer was dried over Na2SO4. Removal of the solvent left a crude mixture, which was purified
by a short silica gel column (dichloromethane/MeOH = 7:3) to yield
a pale yellow solid 2a (1.777 g, 92%). 1H
NMR (500 MHz, DMSO-d6): δ 3.85 (s,
6H), 6.75 (s, 2H), 7.75 (s, 2H). 13C NMR (125 MHz, DMSO-d6): δ 56.01, 104.6, 122.1, 140.0, 151.3.
HRMS (EI): calcd for C9H11N3O2 (M+), 193.0851; found, 193.0849.

General Procedure
for the Synthesis of 3
To a 5 mL microwave reaction
tube, 1 (0.3 mmol), 2a (0.070 g, 0.36 mmol),
K2CO3 (0.124
g, 0.9 mmol), and DMF (3 mL) were added. After stirring at room temperature
for 5 min, the reaction mixture was heated at 110 °C for 1 h
by microwave irradiation (100 W initial power). The mixture was cooled
to room temperature and filtered through a short silica gel column
(ethyl acetate) to eliminate inorganic components. Evaporation of
the solvent under reduced pressure gave a crude mixture, which was
purified by TLC (dichloromethane/methanol = 97/3) to give 3. Spectroscopic data for all products are shown below.

8,11-Dimethoxy-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]quinazoline (3a)
Rf = 0.34. Pale yellow solid (58 mg, 68%). mp 192–195
°C. 1H NMR (500 MHz, CDCl3): δ 1.86–1.90
(m, 2H), 1.93–1.98 (m, 2H), 2.85–2.87 (m, 2H), 3.04–3.07
(m, 2H), 4.02 (s, 3H), 4.07 (s, 3H), 6.61 (d, J =
8.6 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 8.90 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 22.5, 22.6, 26.3,
33.8, 55.9, 56.9, 100.9, 106.3, 116.9, 117.5, 133.7, 136.8, 143.5,
145.6, 149.5, 165.9. HRMS (EI): calcd for C16H17N3O2 (M+), 283.1321; found, 283.1318.

8,11-Dimethoxy-3-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]quinazoline (3b)
Rf = 0.35. Pale yellow solid (50 mg, 56%). mp 179–181
°C. 1H NMR (500 MHz, CDCl3): δ 1.14
(d, J = 6.6 Hz, 3H), 1.54–1.62 (m, 1H), 1.93–2.01
(m, 1H), 2.02–2.07 (m, 1H), 2.45–2.50 (m, 1H), 2.92–2.96
(m, 1H), 2.99–3.06 (m, 1H), 3.15–3.21 (m, 1H), 4.03
(s, 3H), 4.07 (s, 3H), 6.62 (d, J = 8.6 Hz, 1H),
6.80 (d, J = 8.6 Hz, 1H), 8.91 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 21.5, 28.9, 30.6, 33.2,
34.6, 55.8, 56.9, 100.8, 106.2, 116.4, 117.4, 133.5, 136.8, 143.4,
145.6, 149.5, 165.6. HRMS (EI): calcd for C17H19N3O2 (M+), 297.1477; found, 297.1474.

8,11-Dimethoxy-3-phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]quinazoline (3c)
Rf = 0.32. Pale yellow solid (69 mg, 64%). mp 197–199
°C. 1H NMR (500 MHz, CDCl3): δ 2.10–2.16
(m, 1H), 2.28–2.32 (m, 1H), 2.96–3.02 (m, 1H), 3.06–3.20
(m, 3H), 3.27–3.32 (m, 1H), 4.01 (s, 3H), 4.07 (s, 3H), 6.63
(d, J = 8.6 Hz, 1H), 6.81 (d, J =
8.6 Hz, 1H), 7.26–7.27 (m, 1H), 7.29–7.31 (m, 2H), 7.35–7.38
(m, 2H). 13C NMR (125 MHz, CDCl3): δ 29.7,
33.7, 34.2, 40.1, 55.8, 56.9, 100.9, 106.3, 116.3, 117.4, 126.7, 126.8,
128.7, 133.7, 136.8, 143.4, 144.9, 145.6, 149.5, 165.0. HRMS (EI):
calcd for C22H21N3O2 (M+), 359.1634; found, 359.1632.

9,12-Dimethoxy-2,3,4,5-tetrahydro-1H-benzo[4,5]imidazo[1,2-a]cyclohepta[e]pyrimidine (3d)
Rf = 0.36. Pale yellow solid
(64 mg, 72%). mp 225–226 °C. 1H NMR (500 MHz,
CDCl3): δ 1.74–1.78 (m, 2H), 1.89–1.93
(m, 2H), 1.94–1.99 (m, 2H), 2.87–2.89 (m, 2H), 3.56–3.58
(m, 2H), 3.95 (s, 3H), 4.04 (s, 3H), 6.64 (d, J =
8.6 Hz, 1H), 6.84 (d, J = 8.6 Hz, 1H), 8.47 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 25.1, 27.3, 30.7,
32.0, 34.0, 56.3, 56.4, 102.0, 105.8, 118.8, 122.6, 138.4, 142.3,
145.8, 151.5, 154.0, 156.1. HRMS (EI): calcd for C17H19N3O2 (M+), 297.1477; found,
297.1474.

10,13-Dimethoxy-1,2,3,4,5,6-hexahydrobenzo[4,5]imidazo[1,2-a]cycloocta[e]pyrimidine (3e)
Rf = 0.42. Pale yellow solid
(77 mg, 82%). mp 186–187 °C. 1H NMR (500 MHz,
CDCl3): δ 1.34–1.38 (m, 2H), 1.44–1.49
(m, 2H), 1.72–1.77 (m, 2H), 1.88–1.93 (m, 2H), 2.80–2.82
(m, 2H), 3.65–3.68 (m, 2H), 6.65 (d, J = 8.6
Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 8.45 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 25.7, 26.1, 29.0,
29.4, 29.6, 31.7, 55.9, 56.3, 102.2, 105.3, 118.8, 119.8, 138.0, 141.5,
145.8, 150.7, 151.3, 156.5. HRMS (EI): calcd for C18H21N3O2 (M+), 311.1634; found,
311.1632.

14,17-Dimethoxy-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[4,5]imidazo[1,2-a]cyclododeca[e]pyrimidine (3f)
Rf = 0.47. Pale yellow solid
(83 mg, 75%). mp 195–198 °C. 1H NMR (500 MHz,
CDCl3): δ 1.39–1.46 (m, 8H), 1.50–1.60
(m, 4H), 1.63–1.68 (m, 2H), 1.77–1.83 (m, 2H), 2.78–2.81
(m, 2H), 3.64–3.68 (m, 2H), 6.71 (d, J = 8.6
Hz, 1H), 6.86 (d, J = 8.6 Hz, 1H), 8.57 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 21.9, 22.8, 24.6,
24.7, 25.5, 25.9, 26.5, 27.0, 28.2, 29.7, 56.0, 56.4, 102.3, 105.4,
119.3, 119.5, 138.1, 141.9, 146.0, 151.1, 151.3, 157.6. HRMS (EI):
calcd for C22H29N3O2 (M+), 367.2260; found, 367.2258.

8,11-Dimethoxy-13,14-dihydrobenzo[f]benzo[4,5]imidazo[1,2-a]quinazoline (3g)
Rf = 0.39. Pale yellow
solid (21 mg, 21%). mp 171–174
°C. 1H NMR (500 MHz, CDCl3): δ 3.06–3.09
(m, 2H), 3.21–3.24 (m, 2H), 4.07 (s, 3H), 4.09 (s, 3H), 6.68
(d, J = 8.6 Hz, 1H), 6.82 (d, J =
8.6 Hz, 1H), 7.31–7.32 (m, 2H), 7.35–7.40 (m, 1H), 7.71
(d, J = 7.6 Hz, 1H), 9.45 (s, 1H). 13C
NMR (125 MHz, CDCl3): δ 28.2, 33.2, 56.0, 56.8, 101.6,
106.5, 116.0, 118.0, 122.8, 127.5, 128.4, 128.7, 129.7, 130.2, 136.5,
136.6, 143.4, 145.7, 149.1, 165.7. HRMS (EI): calcd for C20H17N3O2 (M+), 331.1321;
found, 331.1320.

8,11-Dimethoxy[f]benzo[4,5]imidazo[1,2-a]quinazoline (3g′)
Rf = 0.37. Pale yellow solid (35 mg, 35%). mp
194–196 °C. 1H NMR (500 MHz, CDCl3): δ 3.87 (s, 3H), 3.92 (s, 3H), 6.61 (d, J = 8.6 Hz, 1H), 6.66 (d, J = 8.6 Hz, 1H), 7.34–7.37
(m, 1H), 7.45–7.48 (m, 1H), 7.67 (d, J = 7.9
Hz, 1H), 7.88 (d, J = 9.4 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 9.4 Hz, 1H),
9.65 (s, 1H). 13C NMR (125 MHz, CDCl3): δ
56.5, 57.1, 105.0, 105.5, 113.0, 119.3, 120.6, 121.5, 126.7, 128.9,
129.1, 129.4, 130.0, 134.8, 137.3, 138.2, 141.3, 146.7, 150.1, 152.8.
HRMS (EI): calcd for C20H15N3O2 (M+), 329.1164; found, 329.1161.

6,9-Dimethoxy-4-phenylbenzo[4,5]imidazo[1,2-a]pyrimidine (3h)
Rf = 0.27. Pale yellow solid (57 mg, 62%). mp 68–71
°C. 1H NMR (500 MHz, CDCl3): δ 3.11
(s, 3H), 4.06
(s, 3H), 6.45 (d, J = 8.6 Hz, 1H), 6.75 (d, J = 4.2 Hz, 1H), 6.84 (d, J = 8.6 Hz, 1H),
7.43–7.55 (m, 5H), 8.75 (d, J = 4.2 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 55.3, 56.6, 102.1,
106.3, 109.2, 118.6, 126.9, 128.0, 129.7, 136.9, 137.8, 142.3, 145.5,
150.9, 151.7, 154.2. HRMS (EI): calcd for C18H15N3O2 (M+), 305.1164; found, 305.1166.

6,9-Dimethoxy-3-methyl-4-phenylbenzo[4,5]imidazo[1,2-a]pyrimidine (3i)
Rf = 0.38. Pale yellow solid (58 mg, 61%). mp 215–218
°C. 1H NMR (500 MHz, CDCl3): δ 2.13
(s, 3H), 3.06 (s, 3H), 4.04 (s, 3H), 6.36 (d, J =
8.6 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 7.31–7.32
(m, 2H), 7.51–7.53 (m, 3H), 8.67 (s, 1H). 13C NMR
(125 MHz, CDCl3): δ 15.9, 55.6, 56.4, 101.7, 105.7,
115.5, 118.6, 128.2, 128.3, 129.2, 135.6, 137.8, 142.1, 145.4, 147.2,
151.0, 157.4. HRMS (EI): calcd for C19H17N3O2 (M+), 319.1321; found, 319.1319.

3-Butyl-6,9-dimethoxy-4-phenylbenzo[4,5]imidazo[1,2-a]pyrimidine (3j)
Rf = 0.39. Pale yellow solid (73 mg, 67%). mp 148–151
°C. 1H NMR (500 MHz, CDCl3): δ 0.79
(t, J = 7.4 Hz, 3H), 1.19–1.26 (m, 2H), 1.42–1.48
(m, 2H), 2.42–2.45 (m, 2H), 3.06 (s, 3H), 4.04 (s, 3H), 6.36
(d, J = 8.6 Hz, 1H), 6.77 (d, J =
8.6 Hz, 1H), 7.32–7.35 (m, 2H), 7.48–7.53 (m, 3H), 8.69
(s, 1H). 13C NMR (125 MHz, CDCl3): δ 13.6,
22.3, 28.9, 33.4, 55.7, 56.4, 101.7, 105.6, 118.8, 120.4, 128.0, 128.5,
129.2, 135.0, 137.8, 142.1, 145.4, 147.0, 150.8, 157.3. HRMS (EI):
calcd for C22H23N3O2 (M+), 361.1790; found, 361.1788.

3-Isopropyl-6,9-dimethoxy-4-phenylbenzo[4,5]imidazo[1,2-a]pyrimidine (3k)
Rf = 0.34. Pale yellow solid (65 mg, 62%). mp 152–157
°C. 1H NMR (500 MHz, CDCl3): δ 1.22
(d, J = 7.0 Hz, 6H), 2.75–2.84 (m, 1H), 3.06
(s, 3H), 4.04 (s, 3H), 6.35 (d, J = 8.6 Hz, 1H),
6.77 (d, J = 8.6 Hz, 1H), 7.32–7.34 (m, 2H),
7.51–7.53 (m, 3H), 8.83 (s, 1H). 13C NMR (125 MHz,
CDCl3): δ 23.4, 27.5, 55.8, 56.5, 101.7, 105.6, 118.9,
125.4, 128.1, 128.6, 129.2, 134.9, 138.0, 142.1, 145.5, 146.0, 150.6,
154.8. HRMS (EI): calcd for C21H21N3O2 (M+), 347.1634; found, 347.1632.

6,9-Dimethoxy-3,4-diphenylbenzo[4,5]imidazo[1,2-a]pyrimidine (3l)
Rf = 0.41. Pale yellow solid (66 mg, 58%). mp 222–223
°C. 1H NMR (500 MHz, CDCl3): δ 4.02
(s, 3H), 4.09
(s, 3H), 6.68 (d, J = 8.6 Hz, 1H), 6.86 (d, J = 8.6 Hz, 1H), 7.24–7.28 (m, 4H), 7.31–7.37
(m, 4H), 7.51–7.53 (m, 2H), 9.19 (s, 1H). 13C NMR
(125 MHz, CDCl3): δ 55.9, 56.9, 101.6, 106.8, 117.7,
121.3, 127.83, 127.84, 128.7, 129.5, 129.9, 130.2, 136.0, 136.5, 137.4,
137.9, 143.5, 145.7, 149.2, 162.3. HRMS (EI): calcd for C24H19N3O2 (M+), 381.1477;
found, 381.1474.

4-Ethyl-6,9-dimethoxy-3-methylbenzo[4,5]imidazo[1,2-a]pyrimidine (3m)
Rf = 0.42. Pale yellow solid (45 mg, 55%). mp 133–135
°C. 1H NMR (500 MHz, CDCl3): δ 1.41
(t, J = 7.4 Hz, 3H), 2.34 (d, J =
1.1 Hz, 3H), 2.90 (q, J = 7.4 Hz, 2H), 4.03 (s, 3H),
4.08 (s, 3H), 6.62 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 8.89 (q, J = 1.1 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 11.0, 15.8, 29.4,
55.8, 57.1, 100.9, 106.4, 115.3, 117.5, 133.3, 136.6, 143.3, 145.7,
149.8, 169.0. HRMS (EI): calcd for C15H17N3O2 (M+), 271.1321; found, 271.1318.

6,9-Dimethoxy-4-(naphthalen-2-yl)benzo[4,5]imidazo[1,2-a]pyrimidine (3n)
Rf = 0.38. Pale yellow solid (65 mg, 61%). mp 154–157
°C. 1H NMR (500 MHz, CDCl3): δ 2.77
(s, 3H), 4.07 (s, 3H), 6.40 (d, J = 8.6 Hz, 1H),
6.84 (d, J = 8.6 Hz, 1H), 6.86 (d, J = 3.9 Hz, 1H), 7.49 (dd, J = 8.5 and 1.6 Hz, 1H),
7.56–7.62 (m, 2H), 7.90–7.94 (m, 3H), 8.03 (s, 1H),
8.79 (d, J = 3.9 Hz, 1H). 13C NMR (125
MHz, CDCl3): δ 54.9, 56.5, 102.2, 106.3, 109.5, 118.7,
124.5, 126.3, 126.9, 127.28, 127.32, 127.8, 128.4, 132.7, 133.7, 134.3,
137.9, 142.2, 145.6, 150.9, 151.7, 154.2. HRMS (EI): calcd for C22H17N3O2 (M+),
355.1321; found, 355.1318.

4-(Furan-3-yl)-6,9-dimethoxybenzo[4,5]imidazo[1,2-a]pyrimidine (3o)
Rf = 0.36. Pale yellow solid (50 mg, 57%). mp 127–128
°C. 1H NMR (500 MHz, CDCl3): δ 4.05
(s, 3H), 4.10
(s, 3H), 6.63 (dd, J = 3.5 and 1.7 Hz, 1H), 6.67
(d, J = 8.6 Hz, 1H), 6.85 (d, J =
8.6 Hz, 1H), 7.32 (d, J = 7.2 Hz, 1H), 7.49 (dd, J = 3.5 and 0.5 Hz, 1H), 7.64–7.65 (m, 1H), 9.22
(d, J = 7.2 Hz, 1H). 13C NMR (125 MHz,
CDCl3): δ 55.9, 57.2, 101.6, 102.7, 107.1, 111.8,
113.1, 113.5, 118.0, 136.5, 143.3, 144.1, 145.3, 145.6, 152.2, 152.3.
HRMS (EI): calcd for C16H13N3O3 (M+), 295.0957; found, 295.0954.

8,11-Dimethoxybenzo[4,5]imidazo[1,2-a]quinazoline
(3p)
Rf = 0.37.
Pale yellow solid (59 mg, 71%). mp 210–214 °C. 1H NMR (500 MHz, CDCl3): δ 4.06 (s, 3H), 4.07 (s,
3H), 6.89 (s, 2H), 7.52–7.55 (m, 1H), 7.86–7.90 (m,
1H), 7.95 (dd, J = 7.8 and 1.5 Hz, 1H), 9.11 (s,
1H), 9.38 (d, J = 8.7 Hz, 1H). 13C NMR
(125 MHz, CDCl3): δ 56.5, 57.1, 105.2, 105.6, 119.1,
120.3, 121.1, 124.8, 129.2, 133.9, 136.6, 138.0, 141.1, 146.8, 150.0,
158.4. HRMS (EI): calcd for C16H13N3O2 (M+), 279.1008; found, 279.1009.

3-Fluoro-8,11-dimethoxybenzo[4,5]imidazo[1,2-a]quinazoline (3q)
Rf = 0.53. Pale yellow solid (45 mg, 50%). mp 214–217
°C. 1H NMR (500 MHz, CDCl3): δ 4.06
(s, 3H), 4.07
(s, 3H), 6.89 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 7.61–7.64 (m, 2H), 9.07 (s, 1H),
9.44–9.47 (m, 1H). 13C NMR (125 MHz, CDCl3): δ 56.3, 57.0, 105.1, 105.5, 113.7 (d, 2JC–F = 22.0 Hz, 1C), 119.8 (d, 3JC–F = 7.5 Hz, 1C), 120.9, 121.7
(d, 2JC–F = 23.3 Hz,
1C), 122.6 (d, 3JC–F = 7.3 Hz, 1C), 134.5, 136.5, 140.8, 146.8, 149.6, 157.0 (d, 4JC–F = 3.0 Hz, 1C), 158.9
(d, 1JC–F = 246.0 Hz,
1C). HRMS (EI): calcd for C16H12FN3O2 (M+), 297.0914; found, 297.0912.

10,13-Dimethoxybenzo[h]benzo[4,5]imidazo[1,2-a]quinazoline (3r)
Rf = 0.39. Pale yellow
solid (62 mg, 63%). mp 223–225
°C. 1H NMR (500 MHz, CDCl3): δ 3.51
(s, 3H), 4.14 (s, 3H), 6.74 (d, J = 8.6 Hz, 1H),
6.94 (d, J = 8.6 Hz, 1H), 7.45 (dd, J = 7.5 and 7.4 Hz, 1H), 7.72 (dd, J = 7.5 and 7.5
Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.96–7.97 (m, 1H), 8.45–8.47
(m, 1H), 9.17 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 54.7, 56.7, 103.1, 105.8, 116.8, 122.7, 123.1, 123.4,
124.8, 125.2, 126.3, 127.1, 129.6, 135.4, 137.1, 137.6, 143.3, 146.2,
151.6, 156.7. HRMS (EI): calcd for C20H15N3O2 (M+), 329.1164; found, 329.1162.

General Procedure for the Oxidation of 3–4
A solution of CAN (0.165 g, 0.3 mmol) in acetonitrile/H2O (9:1, 2 mL) was added dropwise to a stirred solution of 3 (0.1 mmol) in acetonitrile/H2O (7:3, 2 mL) in
an ice bath. After stirring for 20 min in the ice bath, the reaction
mixture was poured into cold water and then extracted with ethyl acetate
(20 mL, 3 times). Evaporation of the combined solvent under reduced
pressure and recrystallization from dichloromethane and hexane mixture
gave 4.

1,2,3,4-Tetrahydrobenzo[4,5]imidazo[1,2-a]quinazoline-8,11-dione
(4a)
Rf = 0.47.
Brown solid (22 mg, 85%). mp 236–238 °C. 1H
NMR (500 MHz, DMSO-d6): δ 1.79–1.82
(m, 2H), 1.87–1.92 (m, 2H), 2.90–2.92 (m, 2H), 2.98–3.00
(m, 2H), 6.81 (d, J = 10.4 Hz, 1H), 6.87 (d, J = 10.4 Hz, 1H), 9.13 (s, 1H). 13C NMR (125
MHz, DMSO-d6): δ 21.4, 21.6, 25.3,
33.0, 120.7, 123.8, 132.9, 136.4, 137.4, 144.0, 149.3, 166.9, 176.4,
182.2. HRMS (EI): calcd for C14H11N3O2 (M+), 253.0851; found, 253.0854.

3-Methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]quinazoline-8,11-dione (4b)
Rf = 0.54. Brown solid (21 mg, 80%). mp 219–221
°C. 1H NMR (500 MHz, DMSO-d6): δ 1.06 (d, J = 6.6 Hz, 3H), 1.46–1.54
(m, 1H), 1.88–1.99 (m, 2H), 2.36–2.42 (m, 1H), 2.83–2.88
(m, 1H), 2.91–2.98 (m, 1H), 3.07–3.13 (m, 1H), 6.81
(d, J = 10.4 Hz, 1H), 6.87 (d, J = 10.4 Hz, 1H), 8.83 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ 22.7, 30.1, 31.8, 34.4, 35.8, 120.6,
121.6, 134.7, 138.0, 144.6, 146.8, 150.7, 166.8, 178.2, 180.4. HRMS
(EI): calcd for C15H13N3O2 (M+), 267.1008; found, 267.1009.

3-Phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]quinazoline-8,11-dione (4c)
Rf = 0.42. Brown solid (25 mg, 76%). mp 237–239
°C. 1H NMR (500 MHz, DMSO-d6): δ 2.08–2.16 (m, 1H), 2.28–2.32 (m, 1H), 2.96–3.02
(m, 1H), 3.06–3.13 (m, 1H), 3.14–3.20 (m, 2H), 3.27–3.32
(m, 1H), 6.80 (d, J = 10.3 Hz, 1H), 6.89 (d, J = 10.3 Hz, 1H), 7.26–7.27 (m, 1H), 7.29–7.31
(m, 2H), 7.35–7.38 (m, 2H), 8.95 (s, 1H). 13C NMR
(125 MHz, DMSO-d6): δ 29.1, 33.1,
33.6, 38.1, 118.7, 119.8, 126.12, 126.14, 128.1, 133.1, 136.2, 142.8,
144.3, 145.0, 148.8, 164.3, 179.4, 181.5. HRMS (EI): calcd for C20H15N3O2 (M+),
329.1164; found, 329.1162.

2,3,4,5-Tetrahydro-1H-benzo[4,5]imidazo[1,2-a]cyclohepta[e]pyrimidine-9,12-dione (4d)
Rf = 0.58. Brown
solid (19 mg, 71%). mp 190–192 °C. 1H NMR (500
MHz, CDCl3): δ 1.81–1.85 (m, 2H), 1.97–2.04
(m, 4H), 2.94–2.96 (m, 2H), 3.64–3.66 (m, 2H), 6.72
(d, J = 8.6 Hz, 1H), 6.92 (d, J =
8.6 Hz, 1H), 8.54 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 25.1, 27.4, 30.7, 32.0, 34.0, 120.2, 123.2, 132.3, 135.8,
136.8, 143.4, 148.7, 166.3, 175.8, 181.6. HRMS (EI): calcd for C15H13N3O2 (M+),
267.1008; found, 267.1006.

1,2,3,4,5,6-Hexahydrobenzo[4,5]imidazo[1,2-a]cycloocta[e]pyrimidine-10,13-dione (4e)
Rf = 0.56. Brown
solid (23
mg, 81%). mp 194–196 °C. 1H NMR (500 MHz, DMSO-d6): δ 1.25–1.29 (m, 2H), 1.41–1.45
(m, 2H), 1.70–1.74 (m, 2H), 1.76–1.81 (m, 2H), 2.92–2.94
(m, 2H), 3.74–3.76 (m, 2H), 6.85 (d, J = 10.3
Hz, 1H), 6.89 (d, J = 10.3 Hz, 1H), 8.75 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ
25.0, 25.6, 28.0, 28.6, 29.2, 31.4, 123.2, 126.1, 133.9, 140.4, 146.6,
151.3, 151.9, 157.4, 174.3, 182.2. HRMS (EI): calcd for C16H15N3O2 (M+), 281.1164;
found, 281.1167.

1,2,3,4,5,6,7,8,9,10-Decahydrobenzo[4,5]imidazo[1,2-a]cyclododeca[e]pyrimidine-14,17-dione
(4f)
Rf = 0.54.
Brown solid (29 mg, 85%). mp 198–200 °C. 1H
NMR (500 MHz, DMSO-d6): δ 1.41–149
(m, 8H), 1.53–1.63 (m, 4H), 1.66–1.71 (m, 2H), 1.80–1.86
(m, 2H), 2.82–2.85 (m, 2H), 3.67–3.70 (m, 2H), 6.85
(d, J = 10.3 Hz, 1H), 6.91 (d, J = 10.3 Hz, 1H), 8.83 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ 21.6, 21.9, 24.8, 25.1, 25.3, 25.6,
25.7, 26.0, 27.1, 28.7, 123.6, 125.5, 134.0, 140.3, 146.7, 151.1,
151.6, 158.4, 174.5, 182.1. HRMS (EI): calcd for C20H23N3O2 (M+), 337.1790; found,
337.1789.

Benzo[f]benzo[4,5]imidazo[1,2-a]quinazoline-8,11-dione (4g)
Rf = 0.42. Brown solid (24 mg, 81%). mp 223–225
°C. 1H NMR (500 MHz, CDCl3): δ 6.81
(d, J = 10.3 Hz, 1H), 6.88 (d, J = 10.3 Hz, 1H), 7.70–7.73 (m, 1H), 7.81–7.84 (m, 1H),
8.03 (d, J = 8.0 Hz, 1H), 8.34 (d, J = 9.4 Hz, 1H), 8.72 (d, J = 8.4 Hz, 1H), 9.75 (d, J = 9.4 Hz, 1H), 10.07 (s, 1H). 13C NMR (125
MHz, CDCl3): δ 115.8, 118.7, 122.1, 125.7, 128.4,
128.9, 129.6, 130.0, 131.6, 134.9, 136.5, 137.2, 139.7, 146.5, 151.2,
153.9, 175.5, 181.5. HRMS (EI): calcd for C18H9N3O2 (M+), 299.0695; found, 299.0695.

4-Phenylbenzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione
(4h)
Rf = 0.50.
Brown solid (23 mg, 83%). mp 108–110 °C. 1H
NMR (500 MHz, DMSO-d6): δ 6.69 (d, J = 10.4 Hz, 1H), 6.81 (d, J = 10.4 Hz,
1H), 7.44 (d, J = 4.5 Hz, 1H), 7.48–7.53 (m,
2H), 7.55–7.58 (m, 1H), 7.59–7.62 (m, 2H), 8.96 (d, J = 4.5 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ 114.5, 123.4, 127.3, 128.1, 130.5,
133.8, 134.5, 139.1, 146.0, 149.8, 152.2, 155.6, 173.6, 182.3. HRMS
(EI): calcd for C16H9N3O2 (M+), 275.0695; found, 275.0693.

3-Methyl-4-phenylbenzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione
(4i)
Rf = 0.44.
Brown solid (21 mg, 72%). mp 211–212 °C. 1H
NMR (500 MHz, DMSO-d6): δ 2.17 (s,
3H), 6.56 (d, J = 10.4 Hz, 1H), 6.75 (d, J = 10.4 Hz, 1H), 7.47–7.55 (m, 5H), 8.92 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ
15.5, 121.4, 122.9, 128.2, 128.4, 129.8, 132.7, 134.3, 139.2, 145.7,
146.7, 151.3, 158.4, 173.2, 182.2. HRMS (EI): calcd for C17H11N3O2 (M+), 289.0851;
found, 289.0849.

3-Butyl-4-phenylbenzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione
(4j)
Rf = 0.55.
Brown solid (26 mg, 78%). mp 188–191 °C. 1H
NMR (500 MHz, DMSO-d6): δ 0.71 (t, J = 7.4 Hz, 3H), 0.81–0.89 (m, 2H), 1.12–1.19
(m, 2H), 1.38–1.44 (m, 2H), 6.56 (d, J = 10.4
Hz, 1H), 6.75 (d, J = 10.4 Hz, 1H), 7.47–7.57
(m, 5H), 8.95 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ 13.4, 21.6, 28.0, 32.1, 123.1, 125.6, 128.1,
128.6, 129.8, 132.3, 134.2, 139.2, 145.7, 146.7, 151.1, 158.2, 173.2,
182.2. HRMS (EI): calcd for C20H17N3O2 (M+), 331.1321; found, 331.1324.

3-Isopropyl-4-phenylbenzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione (4k)
Rf = 0.44. Brown solid (24 mg, 75%). mp 194–197
°C. 1H NMR (500 MHz, DMSO-d6): δ 1.21 (d, J = 7.0 Hz, 6H), 2.73–2.81
(m, 1H), 6.54 (d, J = 10.3 Hz, 1H), 6.75 (d, J = 10.3 Hz, 1H), 7.46–7.53 (m, 5H), 9.11 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ
22.1, 26.9, 122.6, 127.6, 128.2, 129.3, 130.1, 131.7, 133.7, 138.7,
145.3, 145.4, 150.3, 155.4, 172.6, 181.6. HRMS (EI): calcd for C19H15N3O2 (M+),
317.1164; found, 317.1166.

3,4-Diphenylbenzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione
(4l)
Rf = 0.51.
Brown solid (25 mg, 72%). mp 222–223 °C. 1H
NMR (500 MHz, DMSO-d6): δ 6.91 (d, J = 10.5 Hz, 1H), 6.96 (d, J = 10.5 Hz,
1H), 7.30–7.32 (m, 2H), 7.34–7.37 (m, 2H), 7.40–7.44
(m, 6H), 9.18 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ 121.3, 126.4, 128.1, 128.4, 128.8, 129.59,
129.61, 129.9, 134.8, 135.0, 136.8, 137.2, 137.4, 144.7, 149.2, 162.8,
176.7, 181.9. HRMS (EI): calcd for C22H13N3O2 (M+), 351.1008; found, 351.1010.

4-Ethyl-3-methylbenzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione
(4m)
Rf = 0.47.
Brown solid (18 mg, 74%). mp 173–175 °C. 1H
NMR (500 MHz, DMSO-d6): δ 1.27 (t, J = 7.3 Hz, 3H), 2.36 (d, J = 1.0 Hz, 3H),
2.90 (q, J = 7.3 Hz, 2H), 6.77 (d, J = 10.4 Hz, 1H), 6.83 (d, J = 10.4 Hz, 1H), 9.02
(q, J = 1.0 Hz, 1H). 13C NMR (125 MHz,
DMSO-d6): δ 10.3, 15.0, 28.5, 120.8,
122.8, 132.2, 136.3, 137.3, 143.4, 149.5, 170.1, 176.4, 182.00. HRMS
(EI): calcd for C13H11N3O2 (M+), 241.0851; found, 241.0852.

4-(Naphthalen-2-yl)benzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione
(4n)
Rf = 0.51.
Brown solid (25 mg, 76%). mp 184–187 °C. 1H
NMR (500 MHz, DMSO-d6): δ 6.89 (d, J = 10.4 Hz, 1H), 6.95 (d, J = 10.4 Hz,
1H), 7.64–7.69 (m, 3H), 8.14–8.18 (m, 2H), 8.30 (d, J = 7.2 Hz, 1H), 8.43–8.45 (m, 1H), 8.96 (s, 1H),
9.46 (d, J = 7.2 Hz, 1H). 13C NMR (125
MHz, DMSO-d6): δ 110.3, 116.7, 123.7,
126.8, 127.5, 128.0, 128.4, 128.7, 129.0, 132.6, 132.9, 134.3, 136.1,
136.4, 137.2, 144.6, 150.2, 160.9, 176.6, 181.9. HRMS (EI): calcd
for C20H11N3O2 (M+), 325.0851; found, 325.0850.

4-(Furan-3-yl)benzo[4,5]imidazo[1,2-a]pyrimidine-6,9-dione
(4o)
Rf = 0.45.
Brown solid (19 mg, 72%). mp 157–158 °C. 1H
NMR (500 MHz, DMSO-d6): δ 6.84 (dd, J = 3.6 and 1.8 Hz, 1H), 6.86 (d, J = 10.5
Hz, 1H), 6.91 (d, J = 10.5 Hz, 1H), 7.65 (dd, J = 3.6 and 0.6 Hz, 1H), 7.82 (d, J = 7.2
Hz, 1H), 8.11–8.114 (m, 1H), 9.36 (d, J =
7.2 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ 109.0, 113.6, 115.5, 121.8, 136.5, 136.54, 137.4,
144.6, 147.7, 150.1, 150.6, 152.0, 176.6, 182.0. HRMS (EI): calcd
for C14H7N3O3 (M+), 265.0487; found, 265.0485.

Benzo[4,5]imidazo[1,2-a]quinazoline-8,11-dione
(4p)
Rf = 0.40.
Brown solid (20 mg, 82%). mp 253–255 °C. 1H
NMR (500 MHz, DMSO-d6): δ 6.91 (d, J = 10.3 Hz, 1H), 7.00 (d, J = 10.3 Hz,
1H), 7.84–7.87 (m, 1H), 8.13–8.15 (m, 1H), 8.34–8.36
(m, 1H), 9.49 (s, 1H), 9.60–9.62 (m, 1H). 13C NMR
(125 MHz, DMSO-d6): δ 119.5, 120.0,
126.5, 127.9, 130.0, 134.5, 135.8, 139.3, 144.3, 150.0, 159.7, 175.8,
181.7. HRMS (EI): calcd for C14H7N3O2 (M+), 249.0538; found, 249.0535.

3-Fluorobenzo[4,5]imidazo[1,2-a]quinazoline-8,11-dione
(4q)
Rf = 0.54.
Brown solid (20 mg, 74%). mp 254–257 °C. 1H
NMR (500 MHz, DMSO-d6): δ 6.94 (d, J = 10.3 Hz, 1H), 7.04 (d, J = 10.3 Hz,
1H), 7.90–7.93 (m, 2H), 9.48 (s, 1H), 9.73–9.76 (m,
1H). 13C NMR (125 MHz, DMSO-d6): δ 112.1 (d, 2JC–F = 22.0 Hz, 1C), 118.2 (d, 3JC–F = 7.5 Hz, 1C), 120.1 (d, 2JC–F = 23.3 Hz, 1C), 121.0 (d, 3JC–F = 7.3 Hz, 1C), 126.7, 132.9, 134.9, 139.2, 145.2, 148.0, 155.4 (d, 4JC–F = 3.0 Hz, 1C), 157.3
(d, 1JC–F = 246.0 Hz,
1C), 174.8, 181.8. HRMS (EI): calcd for C14H6FN3O2 (M+), 267.0444; found, 267.0447.

Benzo[h]benzo[4,5]imidazo[1,2-a]quinazoline-10,13-dione (4r)
Rf = 0.43. Brown solid (21 mg, 71%). mp 251–253
°C. 1H NMR (500 MHz, DMSO-d6): δ 6.92 (d, J = 10.3 Hz, 1H), 7.01 (d, J = 10.3 Hz, 1H), 7.68–7.72 (m, 1H), 7.91–7.94
(m, 1H), 8.17 (d, J = 8.4 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.34 (d, J = 8.5 Hz, 1H),
9.66 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ 119.3, 122.2, 123.4, 125.9, 126.3, 127.8,
127.9, 128.8, 130.4, 134.5, 134.8, 139.5, 145.4, 151.5, 158.0, 159.5,
175.0, 182.4. HRMS (EI): calcd for C18H9N3O2 (M+), 299.0695; found, 299.0692.

Supporting Information Available
The Supporting Information is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b02755.Copies of 1H and 13C NMR spectra
(PDF)



Supplementary Material
ao8b02755_si_001.pdf

 The authors declare no
competing financial interest.

Acknowledgments
This research was
supported by the Basic Science
Research Program through the National Research Foundation of Korea
(NRF) funded by the Ministry of Education (2017R1D1A1B03028226). P.D.Q.D.
thanks Y.M. Park Internal Medicine of Geoje Medical Center (Gyeongnam,
Republic of Korea) for partial financial support during his stay in
the Republic of Korea.
==== Refs
References
For synthetic
methods and biological activities
for pyrimidines, see:

a Gogoi J. ; Gogoi P. ; Bezbaruah P. ; Boruah R. C. 
Microwave-assisted Pd-catalyzed synthesis of fused
steroidal and non-steroidal pyrimidines from β-halo-α,β-unsaturated
aldehydes . Tetrahedron Lett. 
2013 , 54 , 7136 –7139 . 10.1016/j.tetlet.2013.10.094 . b Xie F. ; Zhao H. ; Zhao L. ; Lou L. ; Hu Y. 
Synthesis
and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives
for anticancer activity . Bioorg. Med. Chem.
Lett. 
2009 , 19 , 275 –278 . 10.1016/j.bmcl.2008.09.067 .19028425  c Joffe A. M. ; Farley J. D. ; Linden D. ; Goldsand G. 
Trimethoprim-sulfamethoxazole-associated
aseptic meningitis: case reports and review of the literature . Am J. Med. 
1989 , 87 , 332 –338 . 10.1016/s0002-9343(89)80160-3 .2672812  d Xie F. ; Li S. ; Bai D. ; Lou L. ; Hu Y. 
Three-component, one-pot synthesis of 2,4,5-substituted pyrimidines
library for screening against human hepatocellular carcinoma BEL-7402
cells . J. Comb. Chem. 
2007 , 9 , 12 –13 . 10.1021/cc060128y .17206826  e Wang S. ; Wood G. ; Meades C. ; Griffiths G. ; Midgley C. ; McNae I. ; McInnes C. ; Anderson S. ; Jackson W. ; Mezna M. ; Yuill R. ; Walkinshaw M. ; Fischer P. M. 
Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors . Bioorg. Med. Chem. Lett. 
2004 , 14 , 4237 –4240 . 10.1016/j.bmcl.2004.06.012 .15261277  f Atwal K. S. ; O’Neil S. V. ; Ahmad S. ; Doweyko L. ; Kirby M. ; Dorso C. R. ; Chandrasena G. ; Chen B.-C. ; Zhao R. ; Zahler R. 
Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent,
highly selective, and orally bioavailable NHE-1 inhibitors . Bioorg. Med. Chem. Lett. 
2006 , 16 , 4796 –4799 . 10.1016/j.bmcl.2006.06.077 .16870436  g Lagoja I. M. 
Pyrimidine
as constituent of natural biologically active compounds . Chem. Biodiversity 
2005 , 2 , 1 –50 . 10.1002/cbdv.200490173 .h Undheim K. ; Benneche T.   In Comprehensive
Heterocyclic Chemistry II ; Katritzky A. R. , Rees C. W. , Scriven E. F. V.  , Eds.; Pergamon : Oxford , 1996 ; Vol. 6 , p 93 .
For synthetic methods and biological
activities
for 1H-benzo[d]imidazole-4,7-diones,
see:

a Moriarty E. ; Aldabbagh F. 
Synthesis of aryl ring-fused benzimidazolequinones
using 6-exo-trig radical cyclizations . Tetrahedron Lett. 
2009 , 50 , 5251 –5253 . 10.1016/j.tetlet.2009.07.023 . b Gellis A. ; Kovacic H. ; Boufatah N. ; Vanelle P. 
Synthesis and cytotoxicity evaluation
of some benzimidazole-4,7-diones as bioreductive anticancer agents . Eur. J. Med. Chem. 
2008 , 43 , 1858 –1864 . 10.1016/j.ejmech.2007.11.020 .18222567  c O’Donovan L. ; Carty M. P. ; Aldabbagh F. 
First synthesis of N-[(aziridin-2-yl)methyl]benzimidazolequinone and analysis of toxicity
towards normal and Fanconi anemia cells . Chem.
Commun. 
2008 , 5592 –5594 . 10.1039/b814706j . d Hehir S. ; O’Donovan L. ; Carty M. P. ; Aldabbagh F. 
Synthesis
of dimethyl substituted benzimidazoles containing cyclopropane fused
onto five to eight membered [1,2-a]alicyclic rings
and influence of methyl group substituents on cytotoxicity of benzimidazolequinones . Tetrahedron 
2008 , 64 , 4196 –4203 . 10.1016/j.tet.2008.02.093 . e Newsome J. J. ; Colucci M. A. ; Hassani M. ; Beall H. D. ; Moody C. J. 
Benzimidazole- and benzothiazole-quinones: excellent
substrates for NAD(P)H:quinone oxidoreductase 1 . Org. Biomol. Chem. 
2007 , 5 , 3665 –3673 . 10.1039/b713044a .17971996  f Lynch M. ; Hehir S. ; Kavanagh P. ; Leech D. ; O’Shaughnessy J. ; Carty M. P. ; Aldabbagh F. 
Synthesis
by Radical Cyclization and Cytotoxicity of Highly Potent Bioreductive
Alicyclic Ring Fused [1,2-a]Benzimidazolequinones . Chem. —Eur. J. 
2007 , 13 , 3218 –3226 . 10.1002/chem.200601450 .17200920  g Lavergne O. ; Fernandes A.-C. ; Bréhu L. ; Sidhu A. ; Brézak M.-C. ; Prévost G. ; Ducommun B. ; Contour-Galcera M.-O. 
Synthesis
and biological evaluation of novel heterocyclic quinones as inhibitors
of the dual specificity protein phosphatase CDC25C . Bioorg. Med. Chem. Lett. 
2006 , 16 , 171 –175 . 10.1016/j.bmcl.2005.09.030 .16216500  h Aldabbagh F. ; O’Shaughnessy J. 
Synthesis of pyrrolo- and pyrido-[1,2-a]benzimidazolequinone anti-tumor agents containing a fused cyclopropane
ring . Synthesis 
2005 , 2005 , 1069 –1076 . 10.1055/s-2005-861832 . i Baraldi P. G. ; Bovero A. ; Fruttarolo F. ; Preti D. ; Tabrizi M. A. ; Pavani M. G. ; Romagnoli R. 
DNA minor groove binders as potential
antitumor and antimicrobial agents . Med. Res.
Rev. 
2004 , 24 , 475 –528 . 10.1002/med.20000 .15170593  j Garuti L. ; Roberti M. ; Pizzirani D. ; Pession A. ; Leoncini E. ; Cenci V. ; Hrelia S. 
Differential
antiproliferative activity of new benzimidazole-4,7-diones . Farmaco 
2004 , 59 , 663 –668 . 10.1016/j.farmac.2004.04.001 .15262537  k Skibo E. B. ; Islam I. ; Schulz W. G. ; Zhou R. ; Bess L. ; Boruah R. 
The organic chemistry of the pyrrolo[1,2-a]benzimidazole antitumor agents. An example of rational
drug design . Synlett 
1996 , 1996 , 297 –309 . 10.1055/s-1996-5399 .
Batenko N. ; Kricka A. ; Belyakov S. ; Turovska B. ; Valters R. 
A novel method
for the synthesis of benzimidazole-based 1,4-quinone derivatives . Tetrahedron Lett. 
2016 , 57 , 292 –295 . 10.1016/j.tetlet.2015.12.002 .
Dao P. D. Q. ; Ho S. L. ; Cho C. S. 
Synthesis
of N-Fused Benzimidazole-4,7-diones
via Sequential Copper-Catalyzed C-N Coupling/Cyclization and Oxidation . ACS Omega 
2018 , 3 , 5643 –5653 . 10.1021/acsomega.8b00805 .31458764 
a Ho S. L. ; Cho C. S. ; Sohn H.-S. 
Microwave-assisted
copper-powder-catalyzed coupling and cyclization of β-bromo-α,β-unsaturated
carboxylic acids with 1,3-diketones leading to 2H-pyran-2-ones . Synthesis 
2015 , 47 , 216 –220 . 10.1055/s-0034-1379103 . b Jiao Y. ; Ho S. ; Cho C. 
Copper-powder-catalyzed synthesis of pyrimidines from
β-bromo-α,β-unsaturated ketones and amidine hydrochlorides . Synlett 
2015 , 26 , 1081 –1084 . 10.1055/s-0034-1380410 . c Ho S. L. ; Yoon I. C. ; Cho C. S. ; Choi H.-J. 
A recyclable
metal-organic framework MOF-199 catalyst in coupling and cyclization
of β-bromo-α,β-unsaturated carboxylic acids with
terminal alkynes leading to alkylidenefuranones . J. Organomet. Chem. 
2015 , 791 , 13 –17 . 10.1016/j.jorganchem.2015.05.040 . d Dao P. D. Q. ; Ho S. L. ; Lim H.-J. ; Cho C. S. 
Microwave-assisted
cyclization under mildly basic conditions: synthesis of 6H-benzo[c]chromen-6-ones and their 7,8,9,10-tetrahydro
analogues . J. Org. Chem. 
2018 , 83 , 4140 –4146 . 10.1021/acs.joc.8b00048 .29564893 
a Yoo J. ; Ho S. ; Cho C. 
Synthesis of 6H-isoindolo[2,1-a]indol-6-ones via palladium-catalyzed
carbonylative cyclization of 2-(2-bromophenyl)-1H-indoles . Synlett 
2016 , 27 , 1383 –1386 . 10.1055/s-0035-1561560 . b Yang B. W. ; Ho S. L. ; Lim H.-J. ; Cho C. S. 
Palladium-catalyzed
carbonylative cyclization of 2-(2-bromovinyl)benzimidazoles leading
to pyrrolone-fused benzimidazoles . J. Organomet.
Chem. 
2016 , 806 , 83 –87 . 10.1016/j.jorganchem.2015.12.040 . c Dao P. D. Q. ; Lee H. K. ; Sohn H.-S. ; Yoon N. S. ; Cho C. S. 
Synthesis of benzo[4,5]imidazo[1,2-c]pyrimidin-1-amines and their analogs via copper-catalyzed C-N coupling
and cyclization . ACS Omega 
2017 , 2 , 2953 –2958 . 10.1021/acsomega.7b00693 .31457630  d Yang B. W. ; Quang Dao P. D. ; Yoon N. S. ; Cho C. S. 
Copper-catalyzed
C-C coupling and cyclization: Synthesis of benzo[4,5]imidazo[1,2- a]pyridines and benzo[4,5]imidazo[2,1- a ]isoquinolines . J. Organomet. Chem. 
2017 , 851 , 136 –142 . 10.1016/j.jorganchem.2017.09.025 . e Dao P. D. Q. ; Cho C. S. ; Ho S. L. ; Sohn H.-S. 
Microwave-assisted
copper powder-catalyzed synthesis of azole-fused pyrimidinones . Curr. Org. Chem. 
2018 , 22 , 85 –93 . 10.2174/1385272821666170531122318 . f Lee H. ; Dao P. ; Kim Y.-s. ; Cho C. 
Synthesis
of indolo[2,1-a]isoquinolines via copper-catalyzed
C–C coupling and cyclization of 2-(2-bromoaryl)-1H-indoles with 1,3-diketones . Synthesis 
2018 , 50 , 3243 –3249 . 10.1055/s-0036-1591589 .
Ho S. ; Dao P. ; Cho C. 
Microwave-assisted synthesis of benzo[4,5]imidazo[1,2-a]pyrimidines from β-bromo-α,β-unsaturated
aldehydes and 2-aminobenzimidazoles . Synlett 
2017 , 28 , 1811 –1815 . 10.1055/s-0036-1588834 .
For synthetic methods, biological activities,
and fluorescence properties for benzo[4,5]imidazo[1,2-a]pyrimidines, see:

a Bharate S. B. ; Mahajan T. R. ; Gole Y. R. ; Nambiar M. ; Matan T. T. ; Kulkarni-Almeida A. ; Balachandran S. ; Junjappa H. ; Balakrishnan A. ; Vishwakarma R. A. 
Synthesis and evaluation of pyrazolo[3,4-b]pyridines and its structural analogues as TNF-α and IL-6 inhibitors . Bioorg. Med. Chem. 
2008 , 16 , 7167 –7176 . 10.1016/j.bmc.2008.06.042 .18625560  b El-Shekeil A. ; Obeid A. O. ; Al-Aghbari S. 
Anticancer activity studies of some cyclic benzimidazole
derivatives . Eur. J. Chem. 
2012 , 3 , 356 –358 . 10.5155/eurjchem.3.3.356-358.621 . c Algul O. ; Meric A. ; Polat S. ; Yuksek N. D. ; Serin M. S. 
Comparative studies on conventional and microwave-assisted
synthesis of a series of 2,4-di and 2,3,4-trisubstituted benzimidazo[1,2-a] pyrimidines and their antimicrobial activities . Cent. Eur. J. Chem. 
2009 , 7 , 337 –342 . 10.2478/s11532-009-0023-1 . d Werbel L. M. ; Curry A. ; Elslager E. F. ; Hess C. A. ; Hutt M. P. ; Youngstrom C. 
pyrimido[1,2-a]benzimidazoles,2,3-dihydro-1H-cyclopenta[4,5]pyrimido[1,2-a]benzimidazoles,
ands-triazolo[1,5-a]pyrimidines as potential antimalarial
agents . J. Heterocycl. Chem. 
1969 , 6 , 787 –796 . 10.1002/jhet.5570060603 . e Wahe H. ; Asobo P. F. ; Cherkasov R. A. ; Nkengfack A. E. ; Folefoc G. N. ; Fomum Z. T. ; Doepp D. 
Heterocycles of biological
importance: Part 6. The formation of novel biologically active pyrimido[1,2-a]benzimidazoles from electron deficient alkynes and 2-aminobenzimidazoles . ARKIVOC 
2003 , 2003 , 170 –177 . 10.3998/ark.5550190.0004.e16 . f Srivastava R. P. ; Singh S. K. ; Abuzar S. ; Sharma S. ; Gupta S. ; Katiyar J. C. ; Chatterjee R. K. 
Studies
in antiparasitic agents. Part 20. Synthesis of probenzimidazoles,
benzimidazoles and pyrimido[1,2-a]benzimidazoles
as possible anthelmintics . Indian J. Chem.,
Sect. B: Org. Chem. Incl. Med. Chem. 
1993 , 10 , 1035 –1044 . g Kreutzberger A. ; Leger M. 
Antibakterielle Wirkstoffe, 6. Mitt.1) 2,4-Unsymmetrisch dialkylierte
Pyrimido[1,2-a]benzimidazole . Arch. Pharm. 
1982 , 315 , 47 –52 . 10.1002/ardp.19823150111 . h Kreutzberger A. ; Leger M. 
Antiarrhythmika. I. 2,4-dialkylpyrimido[1,2-a]benzimidazole . J. Heterocycl. Chem. 
1981 , 18 , 1587 –1588 . 10.1002/jhet.5570180819 . i Kreutzberger A. ; Leger M. 
Herbizide, 2. Mitt. 2-Trifluormethylpyrimido[1,2-a]benzimidazole . Arch. Pharm. 
1982 , 315 , 438 –443 . 10.1002/ardp.19823150509 . j Zhang Z.-T. ; Qiu L. ; Xue D. ; Wu J. ; Xu F.-F. 
Concise Synthesis
of 2, 3-Diarylpyrimido[1,2-a]benzimidazole Based
on Isoflavones . J. Comb. Chem. 
2010 , 12 , 225 –230 . 10.1021/cc900064q .20039759  k Frolov A. N. 
Heteroaromatic
photocyclization of fluorinated anilinoazines . Russ. J. Org. Chem. 
1998 , 34 , 1047 –1051 . l Tseng S.-S. ; Epstein J. W. ; Brabander H. J. ; Francisco G. 
A simple regioselective synthesis
of pyrimido[1,2-a]benzimidazoles . J. Heterocycl. Chem. 
1987 , 24 , 837 –843 . 10.1002/jhet.5570240357 . m Gao M. ; Wang M. ; Zheng Q.-H. 
Concise and high-yield
synthesis of T808 and T808P for radiosynthesis of [18F]-T808, a PET
tau tracer for Alzheimer’s disease . Bioorg.
Med. Chem. Lett. 
2014 , 24 , 254 –257 . 10.1016/j.bmcl.2013.11.025 .24309505 
Fang S. ; Niu X. ; Yang B. ; Li Y. ; Si X. ; Feng L. ; Ma C. 
One-Pot synthesis of
benzo[4,5]imidazo[1,2-a]quinazoline
derivatives via facile transition-metal-free tandem process . ACS Comb. Sci. 
2014 , 16 , 328 –332 . 10.1021/co500001u .24919956 
Boufatah N. ; Gellis A. ; Maldonado J. ; Vanelle P. 
Efficient microwave-assisted
synthesis of new sulfonylbenzimidazole-4,7-diones: heterocyclic quinones
with potential antitumor activity . Tetrahedron 
2004 , 60 , 9131 –9137 . 10.1016/j.tet.2004.07.070 .
a Rao C. ; Mai S. ; Song Q. 
Cu-catalyzed
synthesis of 3-formyl imidazo[1,2-a]pyridines and
imidazo[1,2-a]pyrimidines by employing ethyl tertiary
amines as carbon sources . Org. Lett. 
2017 , 19 , 4726 –4729 . 10.1021/acs.orglett.7b02015 .28849656  b Beesu M. ; Malladi S. S. ; Fox L. M. ; Jones C. D. ; Dixit A. ; David S. A. 
Human toll-like receptor 8-selective
agonistic activities in 1-alkyl-1H-benzimidazol-2-amines . J. Med. Chem. 
2014 , 57 , 7325 –7341 . 10.1021/jm500701q .25102141  c Valdez J. ; Cedillo R. ; Hernández-Campos A. ; Yépez L. ; Hernández-Luis F. ; Navarrete-Vázquez G. ; Tapia A. ; Cortés R. ; Hernández M. ; Castillo R. 
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives . Bioorg. Med. Chem.
Lett. 
2002 , 12 , 2221 –2224 . 10.1016/s0960-894x(02)00346-3 .12127542  d Frei R. ; Breitbach A. S. ; Blackwell H. E. 
2-Aminobenzimidazole
Derivatives Strongly Inhibit and Disperse Pseudomonas aeruginosa Biofilms . Angew. Chem., Int. Ed. 
2012 , 51 , 5226 –5229 . 10.1002/anie.201109258 .
Khan K. M. ; Khan I. ; Perveen S. ; Malik M. I. 
A rapid and efficient
CsF catalyzed tandem Knoevenagel-Michael reaction . J. Fluorine Chem. 
2014 , 158 , 1 –5 . 10.1016/j.jfluchem.2013.11.010 .
a Li C. ; Zhang W.-T. ; Wang X.-S. 
CuI-catalyzed
C-N bond formation and cleavage for the synthesis of benzimidazo[1,2-a]quinazoline derivatives . J. Org.
Chem. 
2014 , 79 , 5847 –5851 . 10.1021/jo5007398 .24885515  b Kumar P. ; Singh A. K. ; Bahadur V. ; Len C. ; Richards N. G. J. ; Parmar V. S. ; Van der Eycken E. V. ; Singh B. K. 
Microwave-assisted, metal-free, base-mediated C-N bond
formation/cleavage: synthesis of benzimidazo[1,2-a]quinazoline derivatives . ACS Sustainable Chem.
Eng. 
2016 , 4 , 2206 –2210 . 10.1021/acssuschemeng.5b01669 .
Da
Settimo A. ; Primofiore G. ; Da Settimo F. ; Pardi G. ; Simorini F. ; Marini A. M. 
An approach to novel
fused triazole or tetrazole derivatives starting from benzimidazo[1,2-a]quinazoline-5(7H)-one and 5,7-dihydro-5-oxopyrido[3′,2′:5,6]pyrimido[1,2-a]benzimidazole . J. Heterocycl. Chem. 
2002 , 39 , 1007 –1011 . 10.1002/jhet.5570390523 .
a Jardim G. A. M. ; Bower J. F. ; da Silva
Júnior E. N. 
Rh-catalyzed reactions of 1,4-benzoquinones with electrophiles:
C-H iodination, bromination, and phenylselenation . Org. Lett. 
2016 , 18 , 4454 –4457 . 10.1021/acs.orglett.6b01586 .27599589  b Sanna V. ; Nurra S. ; Pala N. ; Marceddu S. ; Pathania D. ; Neamati N. ; Sechi M. 
Targeted nanoparticles
for the delivery of novel bioactive molecules to pancreatic cancer
cells . J. Med. Chem. 
2016 , 59 , 5209 –5220 . 10.1021/acs.jmedchem.5b01571 .27139920 
a Arnold Z. ; Holý A. 
Synthetic
reactions of dimethylformamide. XIII. β-Bromoacraldehydes . Collect. Czech. Chem. Commun. 
1961 , 26 , 3059 –3073 . 10.1135/cccc19613059 . b Coates R. M. ; Senter P. D. ; Baker W. R. 
Annelative ring
expansion via intramolecular [2 + 2] photocycloaddition of α,β-unsaturated
γ-lactones and reductive cleavage: synthesis of hydrocyclopentacyclooctene-5-carboxylates . J. Org. Chem. 
1982 , 47 , 3597 –3607 . 10.1021/jo00140a001 .
Although 2a is searched on Sci-finder,
no experimental procedure for synthetic method and spectroscopic data
are found.

